For millions of years, frogs have flourished in microbial swamps yet rarely falling ill. To survive these hostile ...

Early clinical trial results suggest that a groundbreaking new antibiotic drug could be a “massive game changer” for some patients suffering from chronic lower back pain.

Wockhardt is planning to exit the US generics business, while American consumers are expected to bear the impact of tariffs ...

A machine which dispenses urgent prescription medicines to patients is described as a European first.

Acquired resistance genes may allow bacteria to degrade or chemically modify antibiotics, rendering them ineffective. They ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

The risk for moderate to severe infection in later childhood was associated with overall infection burden in early life.

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as ...

Akagera Medicines, a Rwandan biotech company has announced promising results after completing early stages of preclinical ...

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.